OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Registered number: 07682372 Charity number: 1171827

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

CONTENTS

Page
Reference and administrative details of the Charity, its Trustees and advisers 1
Trustees' report 2 - 6
Independent auditors' report on the financial statements 7 - 10
Statement of financial activities 11
Balance sheet 12 - 13
Statement of cash flows 14
Notes to the financial statements 15 - 31

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2025

Trustees C. Ambrogio
A. Bardelli
R. Bernards
C. Caldas
A. Carracedo
C. Dive
N. Erez
J. Joyce
E. Lianidou
N. Lopez Bigas
E. Oricchio
S. Postel-Vinay
Y. R. Samuels
M. S. Soengas Gonzalez
A. Trumpp
J. K. Westermarck
Company registered
number
07682372
Charity registered
number
1171827
Registered office
Sir Colin Campbell Building
University of Nottingham Innovation Park
Triumph Road
Nottingham
NG7 2TU
Company secretary
J. Smith
Independent auditors
PKF Smith Cooper Audit Limited
Statutory Auditors
2 Lace Market Square
Nottingham
NG1 1PB
Senior management
team
J. Smith, Chief Executive Officer (CEO)

Page 1

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

The Trustees (who are also directors of the charity for the purposes of the Companies Act) present their annual report together with the audited financial statements of the European Association for Cancer Research (EACR) (the Charity) for the 1 January 2025 to 31 December 2025. The Annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the Annual report and financial statements of the Charity comply with the current statutory requirements, the requirements of the Charity's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the Charity qualifies as small under section 382 of the Companies Act 2006, the Strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

Objectives and activities

a. Policies and objectives

The object of the Association is the advancement of cancer research, for the public benefit, from basic research to prevention treatment and care.

b. Strategies for achieving objectives

The EACR aims to achieve its mission by:

c. Activities undertaken to achieve objectives

The EACR supports its members to make progress in researching new ways to prevent, detect and treat cancer by providing education, information, networking and funding opportunities. It also provides information to the public via a free email bulletin and through its website, digital magazine, and podcast.

By supporting cancer researchers in this way, the Association will achieve its purpose of making progress in the fight against cancer, for the benefit of the public.

d. Public benefit

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit. In particular, the Trustees consider how planned activities will contribute to the aim and objectives they have set.

The object of the EACR is the advancement of cancer research, for the public benefit, from basic research to prevention treatment and care. This is achieved by increasing the knowledge of researchers and professionals and fostering greater collaboration amongst those working in the cancer fields, with a view to increasing cancer survival rates and improving treatments for patients.

The Association provides a wide variety of services to its community of members, organises scientific meetings and events, and facilitates communication and collaboration. It also sets out to champion the importance of funding for curiosity-driven scientific research.

Page 2

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Achievements and performance

a. Review of activities

During 2025, the Board’s activities continued to be guided by the Strategic Plan 2024 - 2028. The Board takes advice from an Advisory Council and an Early Career Researchers’ Council. An annual survey of all members ensures that activities continue to develop to meet their needs. Feedback from the 2025 member survey was very positive.

The annual EACR congress was held in Lisbon in June 2025, and was hugely successful, surpassing all previous attendance records by some margin. As usual, several smaller in-person and virtual conferences were held throughout the year, including our most popular ever virtual conference on the new topic of Cancer Plasticity, The virtual conferences, introduced during the pandemic, have become an important part of our offer to those members of the global cancer research community who do not have the resources to travel to in-person events.

We were able to offer a variety of funding opportunities to members in 2025. These include grants to support attendance at our congress and in-person conferences, travel fellowships to support a visit to a host lab in a different country and three-year postdoctoral fellowships to undertake a cancer-related research project in a European institution. We are grateful to partners such as Worldwide Cancer Research and The Mark Foundation for Cancer Research for their support for these initiatives.

Members and the wider public were kept up to date on activities, news and events in the cancer research community via the fortnightly email bulletin, the EACR website, the podcast and the digital magazine, The Cancer Researcher.

EACR member numbers grew by 3% overall in 2025. Notably, however, direct membership (rather than members joining via their affiliated national society) grew by 13%. Membership fees were increased slightly in January 2025.

EACR staffing was stable in 2025. The Scientific Officer role was reviewed and the postholder was promoted to the new role of Scientific Manager, taking on responsibility for the EACR’s funding and awards as well as continuing to lead activities with a scientific focus.

During 2025 we carried out a major project to move to a new finance system more appropriate for our complex needs, which include multiple VAT registrations and multi-currency transactions and reporting. This was a challenging project in terms of staff resources. The transfer was made at year-end and will deliver efficiencies from 2026 onwards.

b. Key management personnel remuneration

All employed staff are appointed to roles which are matched to the University of Nottingham administrative staff salary scale. Terms and conditions of employment also match those of the University, reflecting the EACR’s past association with the University. There is an annual appraisal process, with salary uplifts linked to performance. The CEO’s performance is reviewed by the Executive Committee.

Page 3

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Financial review

a. Going concern

After making appropriate enquiries, the trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

b. Reserves policy

At its June 2024 meeting, the Board reviewed its reserves policy, in line with good governance practice. The policy suggests that in the long term, the EACR should hold reserves between €530,000 and €784,000. Reserves are currently significantly higher than this, but the board has been cognisant of the long-range forecast which shows reserves being eroded in the medium-term. The long-range financial forecast and reserves policy will be reviewed again in June 2026. The financial success of the 2025 congress, and the positive projections for the event in 2026 and 2027 suggest that the long-range forecast will be significantly improved so that some reduction in reserves might be planned for.

c. Principal risks and uncertainties

The Board continued to keep the EACR’s financial position under close review in 2025. The risk register was reviewed in January and October 2025.

The major risk remains the poor performance of an annual congress, or the need to cancel a congress, as the charity relies on the congress for a significant proportion of its income. In 2025, the board commissioned some consultancy work on fundraising from industry and foundations, to assist with income diversification to mitigate this risk. Some of the recommendations made have been implemented, with further consideration to be given to new staffing in this area. The board also approved some significant membership fee increases for 2026, again to assist with income diversification.

d. Financial risk management

The Trustees have assessed the major risks to which the Charity is exposed, in particular those related to the operations and finances of the Charity, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks. The risk register is reviewed and updated at least twice each year.

e. Principal funding

The EACR receives funds from grants and donations, partnership agreements, membership fees, conference attendance fees, sponsorship and advertising.

f. Fundraising

The EACR does not employ professional fundraisers. The public are invited to donate to the EACR through a link on the website to the EACR’s JustGiving page.

g. 2025 review and closing position

In 2025, the charity's funds increased by £213,959. The outcome brings the charity’s funds to £1,877,085.

Page 4

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Structure, governance and management

a. Constitution

EACR is a company limited by guarantee (07682372) and a registered charity in England and Wales (1171827).

b. Methods of appointment or election of Trustees

The management of the charity is the responsibility of the 16 trustees who are elected and co opted under the terms of the Articles of Association: https://eacr.org/governance/constitution.

EACR members are invited to make nominations for new Board members. Nominations are considered by a Nominating Committee which advises the Board on its proposals for the appointment of members of the Board. The Nominating Committee sets out to recommend nominees of the highest calibre for consideration by the Board and ultimately the approval of the General Assembly. The Board makes nominations for Officers, again for approval by the General Assembly.

New trustees are provided with full information to brief them on their legal obligations under charity and company law. No new Trustees were appointed in 2025.

c. Organisational structure and decision-making policies

The Board of Trustees, which can have between 12 and 16 members, administers the charity. The Board meets at least three times each year. It sets the strategic direction for the organisation, which is implemented by the employed staff, through an annual operational plan. Progress against this operational plan is monitored annually by the Board, along with a review at every meeting of financial performance against budget, and updated budget forecasts. A KPI reporting dashboard was introduced in 2023 and is reviewed annually by the management team and the Board.

The current strategic plan is available at: https://eacr.org/governance/strategic-plan. The Executive Committee, consisting of the President, President Elect, Past President, Secretary General and Treasurer, has devolved authority to take decisions between Board meetings. The Committee, plus the CEO, meets by video call once every month. All decisions taken by this Committee are reported to the Board at the next full Board meeting.

Plans for future periods

The Strategic Plan sets out the EACR’s plans for 2024 - 2028. In line with the plan to reduce reserves over time once the long-range forecast allows, the charity aims to introduce new funding opportunities for its members, to support them in their research. Career development and new online networking opportunities will continue to be developed and reviewed.

Funds held as custodian

Funds held as custodian are £nil at 31 December 2025.

Page 5

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Statement of Trustees' responsibilities

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

Auditors

The auditors, PKF Smith Cooper Audit Limited, have indicated their willingness to continue in office. The designated Trustees will propose a motion reappointing the auditors at a meeting of the Trustees.

Approved by order of the members of the board of Trustees and signed on their behalf by:

................................................ Y. R. Samuels Chair of Trustees Date: 1 May 2026

Page 6

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE TRUSTEES OF EUROPEAN ASSOCIATION FOR CANCER RESEARCH

Opinion

We have audited the financial statements of European Association for Cancer Research (the 'charitable company') for the year ended 31 December 2025 which comprise the Statement of financial activities, the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Page 7

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE TRUSTEES OF EUROPEAN ASSOCIATION FOR CANCER RESEARCH (CONTINUED)

Other information

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Page 8

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE TRUSTEES OF EUROPEAN ASSOCIATION FOR CANCER RESEARCH (CONTINUED)

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the company and industry, we identify the key laws and regulations affecting the company. We identified that the principal risk of fraud or non-compliance with laws and regulations related to:

We focussed on those areas that could give rise to a material misstatement in the Society's financial statements. Our procedures included, but were not limited to:

It is the primary responsibility of management, with the oversight of those charged with governance, to ensure that the entity's operations are conducted in accordance with the provisions of laws and regulations and for the prevention and detection of fraud.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

Page 9

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE TRUSTEES OF EUROPEAN ASSOCIATION FOR CANCER RESEARCH (CONTINUED)

Use of our report

This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

PKF Smith Cooper Audit Limited

Statutory Auditors 2 Lace Market Square Nottingham NG1 1PB

Date: 1 May 2026

PKF Smith Cooper Audit Limited are eligible to act as auditors in terms of section 1212 of the Companies Act 2006.

Page 10

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025

Note
Income from:
Donations and legacies
4
Charitable activities:
5
Membership income
Meeting & conference income
Investments
6
Other income
7
Total income
Expenditure on:
Raising funds
8
Charitable activities
9
Total expenditure
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward
Unrestricted
funds
2025
£
209,809
298,061
2,239,825
43,607
19,418
2,810,720
5,253
2,591,508
2,596,761
213,959
1,663,126
1,877,085
Restricted
funds
2025
£
51,009
-
-
-
-
51,009
-
51,009
51,009
-
-
-
Total
funds
2025
£
260,818
298,061
2,239,825
43,607
19,418
2,861,729
5,253
2,642,517
2,647,770
213,959
1,663,126
1,877,085
Total
funds
2024
£
231,979
300,391
1,930,946
56,447
22,896
2,542,659
8,334
2,711,186
2,719,520
(176,861)
1,839,987
1,663,126

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 15 to 31 form part of these financial statements.

Page 11

EUROPEAN ASSOCIATION FOR CANCER RESEARCH (A company limited by guarantee) REGISTERED NUMBER: 07682372

BALANCE SHEET AS AT 31 DECEMBER 2025

Note
Fixed assets
Tangible assets
15
Current assets
Debtors due after more than 1 year
16
Debtors due within 1 year
16
Investments
17
Cash at bank and in hand
Current liabilities
Creditors: amounts falling due within one
year
18
Net current assets
Total assets less current liabilities
Creditors: amounts falling due after more
than one year
19
Total net assets
Charity funds
Restricted funds
21
Unrestricted funds
21
Total funds
22,094
574,026
216,783
1,991,758
2,804,661
(844,293)
2025
£
2,122
2,122
1,960,368
1,962,490
(85,405)
1,877,085
-
1,877,085
1,877,085
34,482
446,190
200,000
1,806,007
2,486,679
(755,428)
2024
£
2,713
2,713
1,731,251
1,733,964
(70,838)
1,663,126
-
1,663,126
1,663,126

Page 12

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee) REGISTERED NUMBER: 07682372

BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2025

The entity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the entity to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

However, an audit is required in accordance with section 144 of the Charities Act 2011.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Y. R. Samuels Chair of Trustees Date: 1 May 2026

The notes on pages 15 to 31 form part of these financial statements.

Page 13

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2025

Cash flows from operating activities
Net cash provided by/(used in) operating activities (Note 24)
Cash flows from investing activities
Purchase of tangible fixed assets
Bank interest income
Net cash provided by investing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year (Note 25)
2025
£
160,227
(1,300)
43,607
42,307
202,534
2,006,007
2,208,541
2024
£
(298,310)
(1,265)
56,447
55,182
(243,128)
2,249,135
2,006,007

The notes on pages 15 to 31 form part of these financial statements

Page 14

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. General information

European Association for Cancer Research presents its financial statements for the year ended 31 December 2025.

The Charity is a private company limited by guarantee incorporated in the UK. The registered office address is Sir Colin Campbell Building, University of Nottingham Innovation Park, Triumph Road, Nottingham, NG7 2TU.

The Charity's registered number is 1171827.

The Charity's principal activity during the year continued to be that of raising funds for the advancement of cancer research, through memberships, sponsorships, meetings and events.

A summary of the Charity's accounting policies, which have been consistently applied, is set out below:

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements are presented in sterling and are rounded to the nearest £1.

European Association for Cancer Research meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Company status

The Charity is a company limited by guarantee. The members of the Charity are the Trustees named on page 1. In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the Charity.

2.3 Going concern

After making appropriate enquiries, the trustees have reasonable expectation that the Charity has adequate resources to continue in operational existence for the forseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

2.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

Page 15

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

2. Accounting policies (continued)

2.5 Incoming Resources

All incoming resources are included in the Statement of Financial Activities when the Charity has entitlement to the funds, certainty of receipt and the amount can be measured with sufficient reliability.

Income from grants are recognised when the Charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

Donations are recognised when the Charity has been notified of both the amount and the settlement date. In the event that a donation is subject to conditions that require a level of performance by the Charity before the Charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the Charity and it is probable that these conditions will be fulflled within the reporting period.

Meeting and conference income is recognised once Charity has entitlement to the funds, certainty of receipt and the amount can be measured with sufficient reliability - usually this is at the time of the relevant meeting/conference taking place.

Membership income is deferred and recognised evenly over the duration of the membership.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

2.6 Expenditure

Expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities, they have been allocated on a basis consistent with the use of resources.

Costs of raising funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the Charity’s operations, including support costs and costs relating to the governance of the Charity apportioned to charitable activities.

All costs are incurred in the pursuit of the charitable aims of the Charity. The cost base is split into direct variable costs of running events, and operational overheads incurred in the ordinary course of business. Those overheads are disclosed in the accounts as “support costs”; these include gains/losses on foreign exchange and non-recoverable foreign VAT. The most significant element of support costs is the salary cost, which along with certain other overheads form the fixed costs of the company.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

2.7 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

Page 16

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

2. Accounting policies (continued)

2.8 Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Statement of Financial Activities.

2.9 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a Charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2.10 Tangible fixed assets and depreciation

Tangible fixed assets costing £100 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment - 25% straight line

2.11 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.12 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Page 17

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

2. Accounting policies (continued)

2.13 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation.

2.14 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.15 Operating leases

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight-line basis over the lease term.

2.16 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

3. Critical accounting estimates and areas of judgment

In the application of the Charity’s accounting policies, which are described in Note 2, management is required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of revision and future periods if the revision affects both current and future years.

The Trustees have not identified any critical judgements or key sources of estimation uncertainty in preparing these financial statements.

Page 18

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

4. Income from donations and legacies

Unrestricted
funds
2025
Restricted
funds
2025
£
£
Donations
16,217
-
Grants
193,592
51,009
209,809
51,009
Unrestricted
funds
2024
Restricted
funds
2024
£
£
Donations
18,823
-
Grants
173,361
39,795
192,184
39,795
Income from charitable activities
Unrestricted
funds
2025
£
Membership income
298,061
Meeting and conference income
2,239,825
2,537,886
Unrestricted
funds
2024
£
Membership income
300,391
Meeting and conference income
1,930,946
2,231,337
Total
funds
2025
£
16,217
244,601
260,818
Total
funds
2024
£
18,823
213,156
231,979
Total
funds
2025
£
298,061
2,239,825
2,537,886
Total
funds
2024
£
300,391
1,930,946
2,231,337

5. Income from charitable activities

Page 19

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

6. Investment income

Unrestricted
funds
2025
£
Bank interest received
43,607
Unrestricted
funds
2024
£
Bank interest received
56,447
Total
funds
2025
£
43,607
Total
funds
2024
£
56,447

Page 20

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

7. Other incoming resources

Other incoming resources
Other incoming resources
Unrestricted
funds
2025
£
19,418
Unrestricted
funds
2024
£
22,896
Total
funds
2025
£
19,418
Total
funds
2024
£
22,896

8. Expenditure on raising funds

Costs of raising voluntary income

Unrestricted Total
funds funds
2025 2025
£ £
Fundraising expenses 5,253 5,253

Page 21

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

8. Expenditure on raising funds (continued)

Costs of raising voluntary income (continued)

Unrestricted Total
funds funds
2024 2024
£ £
Fundraising expenses 8,334 8,334

9. Analysis of expenditure on charitable activities

Summary by fund type

Unrestricted
funds
2025
£
Direct and support costs
2,591,508
Unrestricted
funds
2024
£
Direct and support costs
2,671,391
Analysis of expenditure by activities
Activities
undertaken
directly
2025
£
Charitable activity
1,702,562
Restricted
funds
2025
£
51,009
Restricted
funds
2024
£
39,795
Support
costs
2025
£
939,955
Total
2025
£
2,642,517
Total
2024
£
2,711,186
Total
funds
2025
£
2,642,517

10. Analysis of expenditure by activities

Page 22

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

10. Analysis of expenditure by activities (continued)

Activities
undertaken Support Total
directly costs funds
2024 2024 2024
£ £ £
Charitable activity 1,805,951 905,235 2,711,186

Analysis of support costs

Staff costs
Depreciation
Rent (operating leases)
Office costs
Computer costs
Staff training
Travelling expenses and entertainment
Legal and professional
Bad debts
Insurance
Bank charges
Sundry expenses
(Profit) / loss on foreign exchange
Governance costs
Total
funds
2025
£
698,445
1,891
40,082
186
43,142
2,853
10,266
78,523
-
28,318
44,433
937
(30,599)
21,478
939,955
Total
funds
2024
£
645,459
4,065
42,041
20
18,642
6,176
12,650
72,620
659
9,559
18,352
2,740
43,376
28,876
905,235

Included within governance costs is £11,235 (2024: £10,600) in respect of auditor's remuneration, £2,120 (2024: £2,000) in respect of auditor's non audit costs and £8,123 (2024: £16,251) in respect of Trustee expenses and other costs in relation to board meetings.

Page 23

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

11. Auditors' remuneration

2025 2024
£ £
Fees payable to the Charity's auditor for the audit of the Charity's annual
accounts 11,235 10,600
Fees payable to the Charity's auditor in respect of:
All non-audit services not included above 2,120 2,000

12. Staff costs

Wages and salaries
Social security costs
Contribution to defined contribution pension schemes
2025
£
560,595
57,858
79,992
698,445
2024
£
514,992
53,463
77,004
645,459

The average number of persons employed by the Charity during the year was as follows:

2025 2024
No. No.
Employees 15 15

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

2025 2024
No. No.
In the band £80,001 - £90,000 - 1
In the band £90,001 - £100,000 1 -

Key management personnel includes the senior management team as detailed on the administrative page.

The key management employee benefits (including employer pension contributions and employer national insurance contributions) for the year totalled £116,628 (2024: £112,456).

Page 24

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL) .

During the year ended 31 December 2025, expenses totalling £ 4,760 were reimbursed or paid directly to to 12 Trustees (2024 - £5,177 to 10 Trustees) .

All expenses relate directly to the attendance at board meetings.

14. Acting as an Agent

During the year, the European Association for Cancer Research acted as an agent on behalf of two other entities. The charity has acted in accordance to with Section 19 of the Charities SORP and no funds are recognised as an asset at year end.

Within the year, the Charity received funds of £288,373 (2024: £28,949) and passed on £288,373 (2024: £54,974). At the reporting date, the net posititon of funds held is a credit to the balance sheet of £Nil (2024: £Nil).

15. Tangible fixed assets

Cost or valuation
At 1 January 2025
Additions
Disposals
At 31 December 2025
Depreciation
At 1 January 2025
Charge for the year
On disposals
At 31 December 2025
Net book value
At 31 December 2025
At 31 December 2024
Office
equipment
£
23,640
1,300
(2,411)
22,529
20,927
1,891
(2,411)
20,407
2,122
2,713

Page 25

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

16. Debtors

Due after more than one year
Prepayments and accrued income
Due within one year
Trade debtors
Other debtors
Prepayments and accrued income
17.
Current asset investments
Unlisted investments (liquid)
18.
Creditors: Amounts falling due within one year
Trade creditors
Other creditors
Accruals and deferred income
19.
Creditors: Amounts falling due after more than one year
Accruals and deferred income
2025
£
22,094
351,848
12,120
210,058
596,120
2025
£
216,783
2025
£
46,718
38,252
759,323
844,293
2025
£
85,405
2024
£
34,482
147,736
63,881
234,573
480,672
2024
£
200,000
2024
£
16,383
25,151
713,894
755,428
2024
£
70,838

Page 26

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

20. Deferred income

Deferred income at 1 January
Resources deferred during the year
Amounts released from previous periods
2025
£
751,258
813,762
(760,010)
805,010
2024
£
891,934
689,665
(830,341)
751,258

Deferred income as at 31 December 2025 is split as £719,605 (2024: £680,421) due < 1 year and £85,405 (2024: £70,838) due > 1 year.

Deferred income as at 31 December 2025 relates to:

21. Statement of funds

Statement of funds - current year

Unrestricted funds
General Funds
Restricted funds
Restricted Funds
Total of funds
Balance at 1
January 2025
£
1,663,126
-
1,663,126
Income
£
2,810,720
51,009
2,861,729
Expenditure
£
(2,596,761)
(51,009)
(2,647,770)
Balance at 31
December 2025
£
1,877,085
-
1,877,085

Page 27

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

21. Statement of funds (continued)

Statement of funds - prior year Balance at
1 January 2024
£
1,839,987
Income
£
2,502,864
39,795
2,542,659
Expenditure
£
(2,679,725)
(39,795)
(2,719,520)
Balance at
31 December 2024
£

1,663,126
-
Unrestricted funds
General Funds
Restricted funds
Restricted Funds
Total of funds
-
1,839,987
1,663,126

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes.

22. Summary of funds

Summary of funds - current year

General funds
Restricted funds
Balance at 1
January 2025
£
1,663,126
-
1,663,126
Balance at
1 January 2024
£
1,839,987
-
1,839,987
Income
£
2,810,720
51,009
2,861,729
Income
£
2,502,864
39,795
2,542,659
Expenditure
£
(2,596,761)
(51,009)
(2,647,770)
Expenditure
£
(2,679,725)
(39,795)
(2,719,520)
Balance at 31
December 2025
£
1,877,085
-
1,877,085
Balance at
31 December 2024
£
1,663,126
-
Summary of funds - prior year
General funds
Restricted funds
1,663,126

Page 28

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

23. Analysis of net assets between funds

Analysis of net assets between funds - current year

Unrestricted
funds
2025
£
Tangible fixed assets
2,122
Debtors due after more than one year
22,094
Current assets
2,782,567
Creditors due within one year
(844,293)
Creditors due in more than one year
(85,405)
Total
1,877,085
Total
funds
2025
£
2,122
22,094
2,782,567
(844,293)
(85,405)
1,877,085

Analysis of net assets between funds - prior year

Tangible fixed assets
Debtors due after more than one year
Current assets
Creditors due within one year
Creditors due in more than one year
Total
Unrestricted
funds
2024
£
2,713
34,482
2,452,197
(755,428)
(70,838)
1,663,126
Total
funds
2024
£
2,713
34,482
2,452,197
(755,428)
(70,838)
1,663,126

Page 29

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

24. Reconciliation of net movement in funds to net cash flow from operating activities

Net income/(expenditure) for the year (as per Statement of Financial
Activities)
Adjustments for:
Depreciation charges
(Increase)/decrease in debtors
Increase/(decrease) in creditors
Investment income
Net cash provided by/(used in) operating activities
2025
£
213,959
1,891
(115,448)
103,432
(43,607)
160,227
2024
£
(176,861)
4,065
94,138
(163,205)
(56,447)
(298,310)

25. Analysis of cash and cash equivalents

2025 2024
£ £
Cash in hand 1,991,758 1,806,007
Term deposits 216,783 200,000

26. Analysis of changes in net debt

Cash at bank and in hand
Liquid investments
At 1
January
2025
£
1,806,007
200,000
2,006,007
Cash flows
£
185,751
16,783
202,534
At 31
December
2025
£
1,991,758
216,783
2,208,541

27. Pension commitments

The Charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Charity in an independently administered fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £79,992 (2024: £77,004). Contributions totalling £20,472 (2024 £9,680) were payable to the fund at the balance sheet date and are included in creditors.

Page 30

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

28. Operating lease commitments

At 31 December 2025 the Charity had commitments to make future minimum lease payments under noncancellable operating leases as follows:

2025 2024
£ £
Not later than 1 year 26,544 26,760

Page 31